Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
March 2017
-
In The NewsWorld Malaria Report 2016: keeping up the momentumHarald Nusser, Head of Novartis Social Business shares his insights from the launch of the World Malaria report 2016 in London.
-
In The NewsAt a Juncture in Malaria EradicationHarald Nusser, Head of Novartis Social Business reflects on the chance of reaching a malaria-free world within our generation.
-
In The NewsWhat is really driving malaria control is the personal accountability and passion of community health workersHarald Nusser, Head of Novartis Social Business shares his insights following the latest National Malaria Control Program best practice sharing workshop in Dakar.
February 2017
-
Rare Every Day: Experiences, challenges and victories of the rare disease community
-
Media ReleaseNovartis Aktionäre genehmigen an der ordentlichen Generalversammlung alle Anträge des VerwaltungsratsAktionäre genehmigen für 2016 die 20. Dividendenerhöhung in Folge auf CHF 2,75 pro Aktie (+2%) - dies entspricht einer Rendite von 3,5% und einer Ausschüttungsquote von circa 69% des Free Cashflow…
-
Media ReleaseNovartis shareholders approve all resolutions proposed by Board of Directors at the Annual General MeetingShareholders approve 20th consecutive dividend increase to CHF 2.75 (+2%) per share for 2016; representing a 3.5% yield and approximately 69% payout of free cash flow Dr. Joerg Reinhardt…
-
Media ReleaseLes actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration lors de l'Assemblée générale annuelleLes actionnaires approuvent la 20e hausse consécutive du dividende, à CHF 2,75 (+2 %) par action au titre de l'exercice 2016. Cela représente un rendement de 3,5 % et une distribution du free cash-…
-
Media ReleaseNovartis receives positive CHMP opinion for Tafinlar® + Mekinist® in BRAF-positive non-small cell lung cancer (NSCLC) patientsIf approved, Tafinlar + Mekinist will be the first targeted therapy specifically for NSCLC patients with a BRAF V600 mutation CHMP opinion based on positive data from pivotal study of patients…
-
Meet T.J. Sharpe
Meet Melanoma survivor TJ Sharpe in the first installment of his new blog series on Novartis.com.
-
In The NewsNovartis Access perspectives: Pharma partners with African countries on chronic diseasesIn an editorial for Pharmaphorum, Dr. Kiliko, Head Customer Services at Mission for Essential Drugs and Supplies (MEDS), showcases how Pharma companies play a vital role in improving access-to-…
-
Media ReleaseNovartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLCPriority Review based on Phase III study results showing 16.6 month median progression-free survival in previously untreated ALK+ metastatic NSCLC patients on Zykadia vs. 8.1 months treated with…
-
Media ReleaseSandoz Pharmaceuticals AG a reçu la certification Top Employer Suisse 2017Sandoz Pharmaceuticals AG a été officiellement certifiée par le Top Employers Institute pour les conditions de travail exceptionnelles qu'elle offre à ses employés en SuisseL'étude internationale…
Pagination
- ‹ Previous page
- 1
- …
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- …
- 152
- › Next page